Quasi-chimeric antigen receptor-modified CIK (cytokine induced killer) as well as preparation method and application thereof
A technology of chimeric antigen receptors and cell preparations, which is applied in the field of cell therapy and can solve problems such as high cost, large amount of antibodies, and affecting binding
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0080] Example 1. Preparation and Identification of CIK Cells Similar to Chimeric Antigen Receptor Modification
[0081] The chimeric antigen receptor-modified CIK cells prepared in this example can knock down endogenous CTLA4 expression, and can simultaneously express CTLA4 extracellular region-CD28-41BB-CD3 fusion protein.
[0082] 1. Preparation of CIK cells similar to chimeric antigen receptor modification
[0083] 1. Preparation of lymphocyte medium: serum-free medium containing IL-2 with a final concentration of 300IU / ml and IFN-γ with a final concentration of 1000IU / ml. Wherein, the serum-free medium is the product of Lonza Company, the product number is 04-418Q; the IL-2 is the product of peprotech company, the product number is 200-02; the IFN-γ is the product of peprotech company, the product number is 300-02 .
[0084] 2. Collect the peripheral blood of healthy people (of course, if the peripheral blood of most tumor patients can also be used), after testing that ...
Embodiment 2
[0103] Detection of the killing effect of CIK cells modified by similar chimeric antigen receptors prepared in Example 2 and Example 1 on tumor cells
[0104] First, the human tumor cell line SKOV3 was inoculated on the cell culture plate of the Eisen Live Cell Detection Station. After 12 hours, when the cells grew adherently, a certain amount of CIK (without transfection of any plasmid), CIK-pLV-CTLA4ECD- CD28-41BB-CD3-IRES-miRNA-CTLA4-GFP, CIK-pLV-CTLA4ECD-CD28-41BB-CD3-IRES-miRNA-CTLA4 cells formed different effect-to-target ratios. Continue culturing for 48 hours to detect the killing effect of various CIK cells on tumor cells.
[0105] The result is as Figure 4 As shown, it can be seen from the figure that CIK cells transfected with pLV-CTLA4ECD-CD28-41BB-CD3-IRES-miRNA-CTLA4-GFP or pLV-CTLA4ECD-CD28-41BB-CD3-IRES-miRNA-CTLA4 plasmids have a positive effect on the tumor The killing activity was significantly improved.
[0106] Beijing Ruijian Technology Co., Ltd.
...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com